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114th International Congress on Infectious Diseases (ICID) Abs
Prevalence of HCV by Occult HBV status
Conclusion: Though the overall prevalence of occult HBV
(7%) in our community clinic is lower than historical preva-
lence of 11%, among those not on ARV the prevelance was
much higher (22%). Further, high proportion of patients with
isolated anti HBc also tested positive for HCV ab (47.4%).
Therefore clinicians should have a high index of suspicion
for occult HBV among HIV infected patients whose hepati-
tis panel is positive only for core antibody.Clinicians should
have a high index of suspicion for occult HBV among HIV
infected patients whose hepatitis panel is positive only for
core antibody particularly those not on ARV and with HCV
coinfection.
doi:10.1016/j.ijid.2010.02.515
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Background: Co-infection with hepatitis B virus (HBV) and
HIV is common. Approximately 70-90% of HIV-infected indi-
viduals have evidence of past or active infection with HBV.
It is unclear what predicts the likelihood that patient with
active HBV/HIV infection will receive appropriate surveil-
lance screening for hepatic carcinoma. We hypothesized
that patients who have successful HIV treatment are likely to
have successful hepatic carcinoma surveillance screening.
Methods: To evaluate predictors for surveillance screen-
ing of hepatic carcinoma within the period of July 2008
to June 2009. A retrospective review of medical records
of patients with active HBV and HIV co-infection for hep-
atic ultrasound, alpha fetoprotein (AFP), liver biopsy, HBV
viral load, HBV e Ag screenings and gastroenterologist (GI)
referral.
Results: Of 77 HIV infected patients whose charts were
randomly selected, 55.8% (n =43) obtained care during the
study period. The demographic was 58% male (n=25). 7 of 43
patients (n =16.3%) had active HBV infection. All 7 patients
were referred for hepatic ultrasound, only 43% (n =3) had
the procedure performed with 66% (n =2) abnormal. All 7
patients had AFP screening, hepatitis B DNA measurement,
hepatitis B e Ag screening and GI referral. 1of 7 patients had
an elevated AFP while all 7 had detectable HBV DNA and 43%
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n =3) had positive hepatitis B e antigen. 71% (n =5) had an
nitial GI evaluation while only 28% (n =2) had >1 GI follow
p. 28% (n =2) were no show. None of the 7 patients had liver
iopsy.
In patients who did not obtain an abdominal ultrasound or
ho did not follow up with GI or no show, there was no signif-
cant difference in the CD4 count range when compared to
hose who obtained ultrasound or follow with GI. 57% (n =4)
f patients had issues with adherence as documented in the
hart. All 4 patients did not obtain abdominal ultrasound, 3
id not follow up with GI and 1 was no show.
Conclusion: 16.3% of our cohort of HBV/HIV co-infected
atients had active HBV infection. Non-adherence to fol-
ow up plan is the reason in patients who did not obtain
bdominal ultrasound or GI evaluation. CD4 count did not
ppear to be a predictor of probability to obtain hepatic car-
inoma screening. Strategies that improve adherence will
ikely improve the success of hepatic carcinoma surveillance
creening.
oi:10.1016/j.ijid.2010.02.516
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Background: Tenofovir (TDF) is a nucleotide with dual
ctivity against HIV and hepatitis B (HBV) viruses. Thus, it
as become the antiviral of choice for HIV-HBV co-infected
atients when treatment for both viral infections is indi-
ated.
Methods: We reviewed 19 medical records of patients
ho received tenofovir as part of the antiviral treatment.
ive patients had previously received 3TC (lamivudine) as
art of HAART. Immunological parameters were recorded for
IV infection (CD4/mm3), AST, ALT and viral loads for HIV
nd HBV were followed over an average period of 27 months
range, 3-44m).
Results: All patients were male and the median age was
2 years (range, 29-65). Concomitant antiviral medications
ere 1 NRTI +1 NNRTI (3TC/FTC) in 13 patients, 1 ritonavir-
oosted PI + 1 NNRTI in 1 patient, 1 PI + 1 NRTI (3TC or
TC) in 4 patients and 1 IP ritonavir-boosted + 2NRTI (AZT +
TC) in 1 patient. The mean HBV DNA at baseline was: 6.53
og. Six patients presented at baseline with normal ALT and
3 a mean elevation of AST/ALT x 3,8/x 5. The results of
iver biopsy were available for 6 patients: 1 had cirrhosis,
mild chronic hepatitis (stage 1), 2 moderate chronic hep-
titis (stage 2). 17 patients were HBeAg positive, and two
ere HBeAg negative at baseline. Seven out of 17 patients
